GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (OSL:LYTIX) » Definitions » Policy Acquisition Expense

Lytix Biopharma AS (OSL:LYTIX) Policy Acquisition Expense


View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Lytix Biopharma AS Business Description

Traded in Other Exchanges
Address
Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401 and LTX-315, are in the pipeline. The company operates in Norway and the USA, majority of revenue is from the USA.